Updates in molecular imaging techniques

Hyun, Hoon; Cho, Chong‐Su

doi:10.1007/s13770-019-00222-x

Cited by 6 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Imaging can be used to detect the early stages of cancer and rapidly decide the treatment options [ 139 ]. Various types of imaging agents, including fluorescent dyes, quantum dots, iron oxides, and inorganic nanocrystals are commonly used in molecular imaging modalities such as magnetic resonance imaging (MRI), computed tomography (CT), and photoacoustic (PA) imaging [ 139 , 140 ]. Wo et al have reported FR-targeted PLHNPs coated with gadolinium (Gd-FPLHNPs) for imaging and targeted DOX delivery [ 141 ].…”

Section: Applications Of Polymer-lipid Hybrid Nanoparticlesmentioning

confidence: 99%

Utilization of Polymer-Lipid Hybrid Nanoparticles for Targeted Anti-Cancer Therapy

2020

View full text Add to dashboard Cite

Cancer represents one of the most dangerous diseases, with 1.8 million deaths worldwide. Despite remarkable advances in conventional therapies, these treatments are not effective to completely eradicate cancer. Nanotechnology offers potential cancer treatment based on formulations of several nanoparticles (NPs). Liposomes and polymeric nanoparticle are the most investigated and effective drug delivery systems (DDS) for cancer treatment. Liposomes represent potential DDS due to their distinct properties, including high-drug entrapment efficacy, biocompatibility, low cost, and scalability. However, their use is restricted by susceptibility to lipid peroxidation, instability, burst release of drugs, and the limited surface modification. Similarly, polymeric nanoparticles show several chemical modifications with polymers, good stability, and controlled release, but their drawbacks for biological applications include limited drug loading, polymer toxicity, and difficulties in scaling up. Therefore, polymeric nanoparticles and liposomes are combined to form polymer-lipid hybrid nanoparticles (PLHNPs), with the positive attributes of both components such as high biocompatibility and stability, improved drug payload, controlled drug release, longer circulation time, and superior in vivo efficacy. In this review, we have focused on the prominent strategies used to develop tumor targeting PLHNPs and discuss their advantages and unique properties contributing to an ideal DDS.

show abstract